Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Clearside Biomedical
Deal Size : Inapplicable
Deal Type : Inapplicable
Clearside’s Arctic Vision Gains NDA Acceptance for Uveitic Macular Edema
Details : Arcatus is a proprietary suspension of the corticosteroid triamcinolone acetonide for administration to the suprachoroidal space for the treatment of macular edema associated with uveitis.
Product Name : Arcatus
Product Type : Hormone
Upfront Cash : Inapplicable
February 20, 2025
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Clearside Biomedical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Clearside Biomedical
Deal Size : Inapplicable
Deal Type : Inapplicable
Clearside Biomedical’s Partner Reports Positive Phase 3 Results for ARCATUS® in China
Details :
Product Name : Arcatus
Product Type : Hormone
Upfront Cash : Inapplicable
July 29, 2024
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Clearside Biomedical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Clearside Biomedical
Deal Size : Undisclosed
Deal Type : Collaboration
Clearside & Arctic Vision Partner with Santen for ARVN001 in Uveitic Macular Edema
Details :
Product Name : Arcatus
Product Type : Hormone
Upfront Cash : Undisclosed
July 11, 2024
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Clearside Biomedical
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Clearside Biomedical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : Arcatus
Product Type : Hormone
Upfront Cash : Inapplicable
October 07, 2023
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Clearside Biomedical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Eyenovia
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : MicroLine
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 07, 2022
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Eyenovia
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Loyal Valley Capital
Deal Size : $100.0 million
Deal Type : Series B Financing
Details :
Product Name : Arcatus
Product Type : Hormone
Upfront Cash : Undisclosed
October 03, 2021
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Loyal Valley Capital
Deal Size : $100.0 million
Deal Type : Series B Financing
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Clearside Biomedical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details :
Product Name : Arcatus
Product Type : Hormone
Upfront Cash : Undisclosed
August 15, 2021
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Clearside Biomedical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : ARVN601
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : University of Hong Kong
Deal Size : Undisclosed
Deal Type : Collaboration
Details :
Product Name : ARVN601
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
May 07, 2021
Lead Product(s) : ARVN601
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : University of Hong Kong
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Eyenovia
Deal Size : Inapplicable
Deal Type : Inapplicable
China NMPA Clears Arctic Vision’s IND Application for Phase III study of ARVN003 to Treat Presbyopia
Details :
Product Name : MicroLine
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 09, 2021
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Eyenovia
Deal Size : Inapplicable
Deal Type : Inapplicable